Indications
Treatment of breast cancer with brain metastases
Composition
- Active substance
- etirinotecan pegol
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Onzeald
- Active substance
- etirinotecan pegol
- ATC code
- L01
- Therapeutic area
- Breast Neoplasms
- Marketing authorisation holder
- Nektar Therapeutics UK Limited
- Status
- Refused
- Refused
- 8 Jan 2018
- EMA product number
- EMEA/H/C/003874